In 2014, Nottingham University Hospitals Trust (NUH) took the difficult decision not to publish the results of the long awaited double blind clinical trial into the efficacy of Acoustic CR® Neuromodulation which was run at Nottingham Hearing Biomedical Research Unit, a partner of NUH.
The Tinnitus Clinic recently received this release from NUH which we have reproduced in full with their permission.
RESET 2
“Nottingham University Hospital is disappointed that conclusions cannot be drawn from this trial, because of weaknesses in its design and conduct. We regret that these weaknesses were not identified until the trial was well-advanced, and that as a result we have disappointed, and indeed distressed, patients who participated. We apologise to these patients and to our partners in the research. The patients who volunteered involved naturally expected the trial to give an answer. Regrettably, shortcomings in the trial’s set-up mean it cannot do so, nor properly contribute to the scientific literature and debate in the way we, and our patients, would have wished. Our decision not to publish the results was based solely on the quality of the research. We remain fully committed to undertaking high quality trials which will further advance our understanding of tinnitus and its treatment”.
We understand that the new manufacturers of the Acoustic CR® Neuromodulation device, Neurotherapies Reset Global Distribution Ltd, are planning further clinical studies in this innovative treatment and we will post any information on those trials in this news section.
